首页> 外文期刊>NeuroImage >2/3 receptors and sub-cortical volumes in the human basal ganglia: A PET study with 18 F-MNI-659 and 11 C-raclopride with correction for partial volume effect
【24h】

2/3 receptors and sub-cortical volumes in the human basal ganglia: A PET study with 18 F-MNI-659 and 11 C-raclopride with correction for partial volume effect

机译:人体基底神经节的2/3受体和亚皮质体积:宠物研究,具有18个F-Mni-659和11个C-丙烯普肽,校正部分体积效应

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Abstract Phosphodiesterase 10A enzyme (PDE10A) is an important striatal target that has been shown to be affected in patients with neurodegenerative disorders, particularly Huntington′s disease (HD). PDE10A is expressed on striatal neurones in basal ganglia where other known molecular targets are enriched such as dopamine D 2/3 receptors (D 2/3 R). The aim of this study was to examine the availability of PDE10A enzyme in relation with age and gender and to compare those changes with those related to D 2/3 R and volumes in different regions of the basal ganglia. As a secondary objective we examined the relative distribution of D 2/3 R and PDE10A enzyme in the striatum and globus pallidus. Forty control subjects (20F/20M; age: 44±11y, age range 27–69) from an ongoing positron emission tomography (PET) study in HD gene expansion carriers were included. Subjects were examined with PET using the high-resolution research tomograph (HRRT) and with 3T magnetic resonance imaging (MRI). The PDE10A radioligand 18 F-MNI-659 and D 2/3 R radioligand 11 C-raclopride were used. The outcome measure was the binding potential ( BP ND ) estimated with the two-tissue compartment model ( 18 F-MNI-659) and the simplified reference tissue model ( 11 C-raclopride) using the cerebellum as reference region. The PET data were corrected for partial volume effects. In the striatum, PDE10A availability showed a significant age-related decline that was larger compared to the age-related decline of D 2/3 R availability and to the age-related decline of volumes measured with MRI. In the globus pallidus, a less pronounced decline of PDE10A availability was observed, whereas D 2/3 R availability and volumes seemed to be rather stable with aging. The distribution of the PDE10A enzyme was different from the distribution of D 2/3 R, with higher availability in the globus pallidus. These results indicate that aging is associated with a considerable physiological reduction of the availability of PDE10A enzyme in the striatum. Moreover as result of the analysis, in the striatum for both the molecular targets, we observed a gender effect with higher BP ND the female group. Highlights ? ? 18 F-MNI-659 binding is a measure of Phosphodiestrease 10A enzyme availability. ? ? We examined the effect of age on 18 F-MNI-659 binding in 40 healthy controls. ? ? Age related changes were also evaluated for 11 C-Raclopride and structural volumes. ? ? Patterns of molecular age related changes were evaluated with PVEc. ? ? We found an evident association between age and striatal 18 F-MNI-659 binding.
机译:摘要磷酸二酯酶10A酶(PDE10A)是一种重要的纹状体靶标,已被证明受到神经变性障碍,特别是亨廷顿疾病(HD)的患者的影响。 PDE10A在基底神经节的纹状体神经元中表达,其中富含其他已知的分子靶标如多巴胺D 2/3受体(D 2/3 R)。该研究的目的是研究与年龄和性别相关的PDE10A酶的可用性,并将这些变化与基础神经节的不同地区的D 2/3 R和体积相关。作为次要目标,我们检查了纹状体和Globus Pallidus中D 2/3 R和PDE10A酶的相对分布。包括四十个控制受试者(20F / 20米;年龄:44±11Y,年龄范围27-69),来自HD基因扩张载体的正在进行的正电子发射断层扫描(PET)研究。使用高分辨率研究分层(HRRT)和3T磁共振成像(MRI)用PET检查受试者。使用PDE10A radioligand 18 F-MnI-659和D 2/3 R放射性胶质剂11c-丙烯普普罗德。结果测量是使用将小脑作为参考区域为参考区域的双组织隔室模型(18 F-MNI-659)和简化的参考组织模型(11C-丙烯醚)估计的结合电位(BP ND)。宠物数据被纠正了部分体积效应。在纹状体中,PDE10A可用性显示出与D 2/3 R可用性的年龄相关的下降和使用MRI测量的年龄相关的衰退的年龄相关的下降相比,与年龄相关的衰退进行了重大相关的下降。在Globus pallidus中,观察到PDE10A可用性的不那么明显的下降,而D 2/3 R可用性和卷似乎与老化相当稳定。 PDE10A酶的分布与D 2/3 R的分布不同,具有较高的Globus Pallidus的可用性。这些结果表明,老化与纹状体中PDE10A酶的可用性相当大的生理降低相关。此外,由于分析的结果,在分子靶标中的纹状体中,我们观察到雌性群体高等BP ND的​​性别效应。强调 ?还是18 F-MnI-659结合是磷酸二雌肽10A酶可用性的量度。还是还是我们检查了40例健康对照中的18例F-MNI-659结合的效果。还是还是还评估了11个C-丙烯锌和结构体积的年龄相关变化。还是还是用PVEC评估分子年龄相关变化的模式。还是还是我们发现年龄与纹纹版18 f-mni-659结合之间明显关联。

著录项

  • 来源
    《NeuroImage》 |2017年第2017期|共10页
  • 作者单位

    Karolinska Institutet Department of Clinical Neuroscience Centre for Psychiatry Research;

    Karolinska Institutet Department of Clinical Neuroscience Centre for Psychiatry Research;

    CHDI Foundation/CHDI Management Inc.;

    Karolinska Institutet Department of Clinical Neuroscience Centre for Psychiatry Research;

    Karolinska Institutet Department of Clinical Neuroscience Centre for Psychiatry Research;

    Karolinska Trial Alliance Karolinska University Hospital;

    CHDI Foundation/CHDI Management Inc.;

    CHDI Foundation/CHDI Management Inc.;

    CHDI Foundation/CHDI Management Inc.;

    CHDI Foundation/CHDI Management Inc.;

    Karolinska Institutet Department of Clinical Neuroscience Centre for Psychiatry Research;

    Karolinska Institutet Department of Clinical Neuroscience Centre for Psychiatry Research;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 诊断学;
  • 关键词

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号